Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density - Amgen ( NASDAQ:AMGN )
On Tuesday, a Cantor analyst wrote that additional data from Amgen's experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug.
| Ticker |
Sentiment |
Impact |
|
LLY
|
Neutral
|
17 %
|
|
GS
|
Somewhat Bearish
|
17 %
|
|
AMGN
|
Somewhat Bullish
|
33 %
|
|
NVO
|
Neutral
|
17 %
|
